Loading
A phase 3 trial of Doxorubicin in endometrial cancer, run by GlaxoSmithKline, now recruiting.
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) is a phase 3 interventional study registered as NCT07286331 by GlaxoSmithKline, with 600 participants planned, started 2026-06-04 and due to reach its primary completion in 2028-02-29. Interventions recorded: Mocertatug rezetecan, Paclitaxel and Doxorubicin.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Doxorubicin, Cytotoxic chemotherapy and the tag pipeline.
Shares GSK, Endometrial cancer, Cytotoxic chemotherapy and the tag pipeline.
Shares GSK, Cytotoxic chemotherapy and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK and the tag pipeline.
Shares GSK, Endometrial cancer and the tag pipeline.
Shares GSK, Cytotoxic chemotherapy and the tag pipeline.
Shares Endometrial cancer, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/